Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Gliosarcoma 2Glioma 2Glioblastoma 2Brain Neoplasms 2Medulloblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Temozolomide 14Filgrastim 13Magnetic Resonance Spectroscopy 9Cyclophosphamide 7Carboplatin 7Peripheral Blood Stem Cell Transplantation 6Irinotecan 6Granulocyte Colony-Stimulating Factor 6Etoposide 6X-Rays 5Topotecan 5Thiotepa 5Phantoms, Imaging 5Busulfan 5Biopsy 5Specimen Handling 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Melphalan 4Ifosfamide 4sargramostim 3palbociclib 3olaparib 3etoposide phosphate 3Surgical Procedures, Operative 3Paclitaxel 3ulixertinib 2trioctyl phosphine oxide 2tipifarnib 2tazemetostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × 1-methyltryptophan × Sarcoma × Clear all
NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡